Stockscreener 앱 받기
4.46
3.98%
-0.185
시간 외 거래:
4.35
-0.11
-2.47%
전일 마감가:
$4.645
열려 있는:
$4.67
하루 거래량:
26,446
Relative Volume:
0.55
시가총액:
$208.61M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.89%
1개월 성능:
+22.87%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.455
$4.85
1주일 범위
$4.455
$4.875
52주 변동 폭
$3.4341
$5.10
Capsovision Inc Stock (CV) Company Profile
명칭
Capsovision Inc
전화
(408) 370-4790
주소
18805 COX AVENUE SUITE 250, SARATOGA
CV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
4.46 | 217.27M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 개시 | Roth Capital | Buy |
| 2025-07-28 | 개시 | The Benchmark Company | Speculative Buy |
Capsovision Inc 주식(CV)의 최신 뉴스
CapsoVision's (CV) Sell (E-) Rating Reiterated at Weiss Ratings - MarketBeat
Analyzing Vyome (NASDAQ:HIND) and CapsoVision (NASDAQ:CV) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Short Interest in CapsoVision, Inc. (NASDAQ:CV) Rises By 430.0% - MarketBeat
CapsoVision announces senior leadership transition in clinical operations By Investing.com - Investing.com Nigeria
CapsoVision announces senior leadership transition in clinical operations - Investing.com India
CapsoVision Announces Leadership Transition Plans - TipRanks
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - The Manila Times
AI-Enabled Capsule Endoscopy Leader CapsoVision to Present at ROTH Healthcare Conference in NYC - Stock Titan
CapsoVision (NASDAQ:CV) Stock Price Down 2.2%Should You Sell? - MarketBeat
Financial Analysis: Longevity Health (NASDAQ:XAGE) versus CapsoVision (NASDAQ:CV) - Defense World
CapsoVision CFO Kevin Lundquist Steps Down - TipRanks
CapsoVision chief financial officer steps down; company begins search for successor - Investing.com Australia
CapsoVision CFO Kevin Lundquist Resigns - MarketWatch
Capsovision says Kevin Lundquist steps down as CFOSEC filing - MarketScreener
Ingestible Sensors Market Set for Dynamic Growth with Key Players CapsoVision, Inc., BodyCAP, etectRx - openPR.com
Head to Head Comparison: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Smart Pills Market Worth US$1.30 Billion By 2030 With 11.2% CAGR - Barchart.com
Smart Pills Market worth US$1.30 billion by 2030 with 11.2% CAGR - openPR.com
FY2028 EPS Estimates for CapsoVision Lowered by Roth Capital - MarketBeat
Critical Analysis: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Insider Transactions Reported | CapsoVision(CV)saw insider trading activity on 8/22/2025 - AInvest
FY2028 EPS Estimates for CapsoVision Cut by Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Issues Earnings Results - MarketBeat
CapsoVision 2025 Q2 Earnings Net Loss Narrows 12.2% - AInvest
CapsoVision Reports Second Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Reports Revenue Growth and IPO Success - TipRanks
CapsoVision Revenue Jumps 17 Percent - AOL.com
Smart Pills Company Evaluation Report 2025 | Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies - Yahoo Finance
CapsoVision (NASDAQ:CV) versus ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Comparison - Defense World
Reviewing ReShape Lifesciences (OTCMKTS:RSLSD) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc.'s Quiet Period Set To Expire on August 11th (NASDAQ:CV) - MarketBeat
CapsoVision, Inc.’s (NASDAQ:CV) Quiet Period Will End on August 11th - Defense World
Is capsovision scam - AInvest
Roth Capital Predicts CapsoVision's Q2 Earnings (NASDAQ:CV) - MarketBeat
CapsoVision (NASDAQ:CV) Raised to Strong-Buy at Roth Capital - MarketBeat
Understanding the risks associated with CapsoVision's stock - AInvest
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewswire
Capsovision, Inc. shares fall 2.19% intraday as Kioxia Corporation announces new UFS 4.1 devices for automotive applications. - AInvest
Q2 Earnings Estimate for CapsoVision Issued By Roth Capital - Defense World
Roth Capital Upgrades CapsoVision (NASDAQ:CV) to Strong-Buy - Defense World
Capsovision Inc (CV) 재무 분석
Capsovision Inc (CV)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.83%
자본화:
|
볼륨(24시간):